Published in N Engl J Med on December 01, 2005
The Effects of Aspirin and Acetaminophen on the Stomach in Healthy Volunteers | NCT00594867
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest (2006) 4.50
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ (2009) 3.83
Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol (2014) 3.73
Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest (2006) 3.38
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ (2008) 2.98
The role of aspirin in cancer prevention. Nat Rev Clin Oncol (2012) 2.94
Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation (2012) 2.76
Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology (2007) 2.73
Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol (2012) 2.19
Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients. Crit Care Med (2011) 2.03
Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) (2011) 2.03
Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ (2006) 1.91
Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst (2013) 1.63
Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med (2006) 1.62
Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies. PLoS One (2016) 1.52
Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding. Gastroenterology (2011) 1.44
The treatment of polycythaemia vera: an update in the JAK2 era. Intern Emerg Med (2007) 1.40
Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res (2014) 1.36
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
A randomised trial to evaluate the effects of low-dose aspirin in gestation and reproduction: design and baseline characteristics. Paediatr Perinat Epidemiol (2013) 1.28
Recent advances in antithrombotic therapy after acute coronary syndrome. CMAJ (2013) 1.23
Characteristics of small bowel injury in symptomatic chronic low-dose aspirin users: the experience of two medical centers in capsule endoscopy. J Gastroenterol (2009) 1.18
Therapeutic potential of monoacylglycerol lipase inhibitors. Life Sci (2012) 1.15
Inherited human cPLA(2alpha) deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction. J Clin Invest (2008) 1.12
Gastroduodenal mucosal injury in patients taking low-dose aspirin and the role of gastric mucoprotective drugs: possible effect of rebamipide. J Clin Biochem Nutr (2010) 1.10
Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse. PLoS One (2011) 1.06
Lung Injury Prevention with Aspirin (LIPS-A): a protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injury. BMJ Open (2012) 1.05
NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies. PLoS One (2011) 1.04
Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther (2007) 1.04
Multifunctional actions of approved and candidate stroke drugs. Neurotherapeutics (2009) 1.03
Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care (2009) 1.03
Human cyclooxygenase-1 activity and its responses to COX inhibitors are allosterically regulated by nonsubstrate fatty acids. J Lipid Res (2012) 1.02
Highly electronegative LDL from patients with ST-elevation myocardial infarction triggers platelet activation and aggregation. Blood (2013) 1.00
Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol (2011) 1.00
Case-control study of aspirin use and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2014) 1.00
Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol (2011) 0.99
Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. PLoS One (2014) 0.98
Aspirin for the prevention of colorectal cancer. Best Pract Res Clin Gastroenterol (2011) 0.96
12-lipoxygenase: a potential target for novel anti-platelet therapeutics. Cardiovasc Hematol Agents Med Chem (2011) 0.92
Pre-existent asymmetry in the human cyclooxygenase-2 sequence homodimer. J Biol Chem (2013) 0.92
Protein kinase C regulation of 12-lipoxygenase-mediated human platelet activation. Mol Pharmacol (2011) 0.92
Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers. Clin Pharmacol (2014) 0.91
Risk of Upper Gastrointestinal Bleeding in a Cohort of New Users of Low-Dose ASA for Secondary Prevention of Cardiovascular Outcomes. Front Pharmacol (2010) 0.91
The Effects of EPA+DHA and Aspirin on Inflammatory Cytokines and Angiogenesis Factors. World J Cardiovasc Dis (2011) 0.91
Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. Eur J Epidemiol (2014) 0.91
H(2)S-releasing aspirin protects against aspirin-induced gastric injury via reducing oxidative stress. PLoS One (2012) 0.90
Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanisms. Thrombosis (2012) 0.90
4 years after withdrawal of rofecoxib: where do we stand today? Rheumatol Int (2008) 0.90
OTC analgesics and drug interactions: clinical implications. Osteopath Med Prim Care (2008) 0.89
Potential targets for colorectal cancer prevention. Int J Mol Sci (2013) 0.89
Effects of danshensu on platelet aggregation and thrombosis: in vivo arteriovenous shunt and venous thrombosis models in rats. PLoS One (2014) 0.89
Flavonoids inhibit the platelet TxA(2) signalling pathway and antagonize TxA(2) receptors (TP) in platelets and smooth muscle cells. Br J Clin Pharmacol (2007) 0.89
The effects of EPA, DHA, and aspirin ingestion on plasma lysophospholipids and autotaxin. Prostaglandins Leukot Essent Fatty Acids (2010) 0.89
Niacin and biosynthesis of PGD₂by platelet COX-1 in mice and humans. J Clin Invest (2012) 0.88
Our expanding view of platelet functions and its clinical implications. J Cardiovasc Transl Res (2010) 0.88
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. J Pharmacol Exp Ther (2012) 0.88
Antiplatelet drugs and the perioperative period: What every urologist needs to know. Indian J Urol (2009) 0.87
Thromboxane and the thromboxane receptor in cardiovascular disease. Clin Lipidol (2010) 0.86
Clopidogrel Resistance by P2Y12 Platelet Function Testing in Patients Undergoing Neuroendovascular Procedures: Incidence of Ischemic and Hemorrhagic Complications. J Vasc Interv Neurol (2013) 0.86
Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. Nat Rev Endocrinol (2010) 0.86
Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study. BMC Gastroenterol (2013) 0.86
Increased susceptibility of aging gastric mucosa to injury: the mechanisms and clinical implications. World J Gastroenterol (2014) 0.85
New antithrombotic agents--insights from clinical trials. Nat Rev Cardiol (2010) 0.84
Mechanistic and pharmacological issues of aspirin as an anticancer agent. Pharmaceuticals (Basel) (2012) 0.84
Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on myocardial function and perfusion. J Cardiovasc Pharmacol (2011) 0.84
A combination of aspirin and gamma-tocopherol is superior to that of aspirin and alpha-tocopherol in anti-inflammatory action and attenuation of aspirin-induced adverse effects. J Nutr Biochem (2008) 0.84
The platelet fibrinogen receptor: from megakaryocyte to the mortuary. JRSM Cardiovasc Dis (2012) 0.83
Aspirin: pharmacology and clinical applications. Thrombosis (2011) 0.83
The enteropathy of prostaglandin deficiency. J Gastroenterol (2009) 0.83
Aspirin might reduce the incidence of pancreatic cancer: A meta-analysis of observational studies. Sci Rep (2015) 0.83
Aspirin resistance. Adv Hematol (2009) 0.83
Relationship between platelet and urinary 8-Iso-PGF2α levels in subjects with different degrees of NOX2 regulation. J Am Heart Assoc (2013) 0.83
Aspirin for primary prevention of cardiovascular disease. Thromb J (2015) 0.82
Testing cardiovascular drug safety and efficacy in randomized trials. Circ Res (2014) 0.82
Acetyl salicylic acid protected against heat stress damage in chicken myocardial cells and may associate with induced Hsp27 expression. Cell Stress Chaperones (2015) 0.81
Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. Circ Res (2013) 0.81
Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. Cardiol Res Pract (2012) 0.81
The combination of EPA+DHA and low-dose aspirin ingestion reduces platelet function acutely whereas each alone may not in healthy humans. Prostaglandins Leukot Essent Fatty Acids (2012) 0.81
Exploring clinicians' attitudes about using aspirin for risk reduction in people with Lynch Syndrome with no personal diagnosis of colorectal cancer. Fam Cancer (2016) 0.81
A cyclooxygenase-2-dependent prostaglandin E2 biosynthetic system in the Golgi apparatus. J Biol Chem (2014) 0.80
Platelet interaction with von Willebrand factor is enhanced by shear-induced clustering of glycoprotein Ibα. Haematologica (2013) 0.80
Aspirin inhibit platelet-induced epithelial-to-mesenchymal transition of circulating tumor cells (Review). Biomed Rep (2014) 0.79
Genetic determinants of on-aspirin platelet reactivity: focus on the influence of PEAR1. PLoS One (2014) 0.79
Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insights. World J Gastroenterol (2014) 0.79
Effects of low-dose aspirin and fish oil on platelet function and NF-kappaB in adults with diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids (2013) 0.79
Leukocyte count is associated with increased platelet reactivity and diminished response to aspirin in healthy individuals with a family history of coronary artery disease. Thromb Res (2009) 0.79
Advances in our understanding of "resistance" to antiplatelet agents for prevention of ischemic stroke. Stroke Res Treat (2013) 0.79
Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks. Pharmaceuticals (Basel) (2010) 0.79
Alzheimer's Disease: Fatty Acids We Eat may be Linked to a Specific Protection via Low-dose Aspirin. Aging Dis (2010) 0.79
A systematic review of aspirin in primary prevention: is it time for a new approach? Am J Cardiovasc Drugs (2015) 0.78
In vitro evaluation of aspirin-induced HspB1 against heat stress damage in chicken myocardial cells. Cell Stress Chaperones (2016) 0.78
Is a fecal occult blood test a useful tool for judging whether to perform capsule endoscopy in low-dose aspirin users with negative colonoscopy and esophagogastroduodenoscopy? J Gastroenterol (2016) 0.78
Acetylsalicylic acid for primary prevention of cardiovascular diseases in older patients with diabetes: do the benefits overcome the risks? Ther Adv Drug Saf (2012) 0.78
Aspirin and multiple sclerosis. BMC Med (2015) 0.78
Reconsidering low-dose aspirin therapy for cardiovascular disease: a study protocol for physician and patient behavioral change. Implement Sci (2011) 0.78
Computational Modeling of Competitive Metabolism between ω3- and ω6-Polyunsaturated Fatty Acids in Inflammatory Macrophages. J Phys Chem B (2016) 0.77
Critical views in gastroenterology & hepatology: aspirin prophylaxis: putting gut bleeds into perspective. Gastroenterol Hepatol (N Y) (2014) 0.77
Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. Br J Clin Pharmacol (2016) 0.77
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64
Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med (2009) 10.60
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet (2014) 6.23
Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet (2014) 4.05
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (2015) 3.79
Analyses of cancer data from three ezetimibe trials. N Engl J Med (2008) 3.44
Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. Alcohol Clin Exp Res (2013) 2.84
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood (2004) 2.64
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol (2005) 2.50
Randomized clinical trials--removing unnecessary obstacles. N Engl J Med (2013) 2.43
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41
Management of alcohol dependence in patients with liver disease. CNS Drugs (2013) 2.35
Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol (2009) 2.14
Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer (2003) 1.98
Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol (2011) 1.98
Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med (2007) 1.95
Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol (2004) 1.95
Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One (2012) 1.93
Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol (2006) 1.90
Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol (2003) 1.87
Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: an application to electronic medical records. Pharmacoepidemiol Drug Saf (2011) 1.85
Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis (2004) 1.76
Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 1.74
Anticoagulants in heart disease: current status and perspectives. Eur Heart J (2007) 1.73
Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol (2010) 1.69
Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis (2010) 1.65
Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. J Hepatol (2013) 1.62
Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med (2006) 1.62
Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum (2010) 1.61
Image-enhanced endoscopy with I-scan technology for the evaluation of duodenal villous patterns. Dig Dis Sci (2012) 1.52
Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation. Thromb Haemost (2013) 1.43
Hormone therapy and cerebrovascular events: a population-based nested case-control study. Menopause (2006) 1.43
Incidence and risk factors for atrial fibrillation in patients with newly diagnosed heart failure. J Cardiovasc Med (Hagerstown) (2016) 1.38
Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2013) 1.36
Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J (2004) 1.34
The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis (2006) 1.31
Positive predictive value of computerized medical records for uncomplicated and complicated upper gastrointestinal ulcer. Pharmacoepidemiol Drug Saf (2009) 1.30
Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther (2011) 1.26
The haematocrit and platelet target in polycythemia vera. Br J Haematol (2006) 1.25
Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J (2011) 1.23
Morbidity associated with sleep disorders in primary care: a longitudinal cohort study. Prim Care Companion J Clin Psychiatry (2007) 1.23
Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology (2006) 1.21
Epstein syndrome: another renal disorder with mutations in the nonmuscle myosin heavy chain 9 gene. Hum Genet (2001) 1.15
Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care (2012) 1.12
Nonsteroidal anti-inflammatory drugs and risk of lung cancer. Int J Cancer (2007) 1.12
Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis. PLoS One (2011) 1.11
Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.11
Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol (2010) 1.11
Sensible guidelines for the conduct of large randomized trials. Clin Trials (2008) 1.07
Polymyalgia rheumatica in 2011. Best Pract Res Clin Rheumatol (2012) 1.05
Respiratory medications and the risk of cardiac arrhythmias. Epidemiology (2005) 1.05
Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology (2011) 1.03
Article makes simple errors and could cause unnecessary deaths. BMJ (2002) 1.01
Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica (2008) 1.01
The role of IL-15 in gastrointestinal diseases: a bridge between innate and adaptive immune response. Cytokine Growth Factor Rev (2013) 1.01
Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges. Mol Interv (2009) 1.00
Breast cancer risk among users of antidepressant medications. Epidemiology (2005) 0.99
General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2013) 0.99
Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. The chronic renal impairment in Birmingham (CRIB) study. Nephron Clin Pract (2007) 0.98
Prophylaxis against venous thromboembolism in patients with cancer. N Engl J Med (2014) 0.97
Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care. Drug Saf (2011) 0.94
Cellular mediators of inflammation: tregs and TH17 cells in gastrointestinal diseases. Mediators Inflamm (2010) 0.94
Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels. Clin Endocrinol (Oxf) (2012) 0.92
'Doctor, treat your patient, not your monitor!' Tremor-induced ECG artefacts mimicking torsades de pointes. BMJ Case Rep (2014) 0.91
Cancer incidence in a general population of asthma patients. Pharmacoepidemiol Drug Saf (2006) 0.90
IL-1β biological treatment of familial Mediterranean fever. Clin Rev Allergy Immunol (2013) 0.89
Differential diagnosis of pulmonary embolism in outpatients with non-specific cardiopulmonary symptoms. Intern Emerg Med (2011) 0.89
Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis. Nat Clin Pract Cardiovasc Med (2006) 0.88
Gallbladder disease in the general population: association with cardiovascular morbidity and therapy. Pharmacoepidemiol Drug Saf (2007) 0.87
Clopidogrel-induced neutropenia after coronary stenting: is cilostazol a good alternative? Int J Vasc Med (2011) 0.87
Controversies in COX-2 selective inhibition. J Rheumatol (2002) 0.86
B vitamins for the prevention of vascular disease: insufficient evidence to justify treatment. JAMA (2007) 0.86
A case of variant angina in a patient under chronic treatment with sorafenib. Nat Rev Clin Oncol (2010) 0.85
Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates? Pharmacoepidemiol Drug Saf (2011) 0.85
Angiogenic impairment of the vascular endothelium: a novel mechanism and potential therapeutic target in muscular dystrophy. Arterioscler Thromb Vasc Biol (2013) 0.85
A practical method of measuring glomerular filtration rate by iohexol clearance using dried capillary blood spots. Nephron Clin Pract (2007) 0.85
Tissue-infiltrating lymphocytes analysis reveals large modifications of the duodenal "immunological niche" in coeliac disease after gluten-free diet. Clin Transl Gastroenterol (2012) 0.85
Analyzing partially missing confounder information in comparative effectiveness and safety research of therapeutics. Pharmacoepidemiol Drug Saf (2012) 0.85
Risk of complications after a peptic ulcer diagnosis: effectiveness of proton pump inhibitors. Dig Dis Sci (2013) 0.84
Low-dose aspirin and upper gastrointestinal bleeding in primary versus secondary cardiovascular prevention: a population-based, nested case-control study. Circ Cardiovasc Qual Outcomes (2013) 0.84
Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery. Haematologica (2007) 0.84
Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms. Dig Liver Dis (2012) 0.83
Distinct expression of cyclooxygenase-1 and -2 in the human thymus. Eur J Immunol (2002) 0.83
Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2016) 0.83
Autoimmune hemolytic anemia with gel-based immunohematology tests. Am J Clin Pathol (2013) 0.83
Prescription of antihypertensive medications during pregnancy in the UK. Pharmacoepidemiol Drug Saf (2014) 0.82
Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response. Scand J Gastroenterol (2012) 0.82
Nonsteroidal anti-inflammatory drugs and the heart. Circulation (2014) 0.82
Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice. Eur J Heart Fail (2015) 0.81
IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. J Clin Invest (2015) 0.81
NSAID enteropathy: could probiotics prevent it? J Gastroenterol (2012) 0.81
Use of angiotensin II receptor blockers and the risk of acute pancreatitis: a nested case-control study. Pancreatology (2010) 0.81
A case-control study on the effects of the apolipoprotein E genotypes in nonalcoholic fatty liver disease. Mol Biol Rep (2012) 0.81
Risk factors for falls with use of acid-suppressive drugs. Epidemiology (2013) 0.81
Antibiotic use and the risk of lung cancer. Cancer Epidemiol Biomarkers Prev (2008) 0.80
Angiotensin-converting enzyme inhibitors and risk of esophageal and gastric cancer: a nested case-control study. Clin Gastroenterol Hepatol (2007) 0.80
Epidemiology of meningioma in the United Kingdom. Neuroepidemiology (2012) 0.80
Patterns in the use of low-dose acetylsalicylic acid and other therapies following upper gastrointestinal bleeding. Am J Cardiovasc Drugs (2014) 0.79